Cost of Stem Cells Transplant in Mexico l Placid Answer
In this Video you can get the best answers for your questions about Cost of Stem Cells Transplant in Mexico! http://www.placidway.com/answer-detail/1477/What-is-the-cost-of-stem-cells-transplant-...
By: placidways
Read this article:
Cost of Stem Cells Transplant in Mexico l Placid Answer - Video
Biomarkers of Inflammation
Biomarkers of Inflammation Dipnarine Maharaj, MB.ChB, M.D., FRCP (Edin.), FRCP (Glas.), FRCPath, FACP presents at the 17th Clinical Applications for Age Management Medicine Confernce.
By: AgeManagmentMedicine
See the article here:
Thursday 01/22: Celebrity Transformations; Stem Cell Therapy Debate; Samantha Harris Health Crisis
http://www.thedoctorstv.com Subscribe to The Doctors: http://bit.ly/SubscribeTheDrs LIKE us on Facebook: http://bit.ly/FacebookTheDoctors Follow us on Twitter: http://bit.ly/TheDrsTwitter Follow...
By: The Doctors
See the original post here:
The New Stem Cell Therapy 2015
Regener8 Hair.
By: Regener8 Hair
Read the original here:
By Amy Norton HealthDay Reporter
TUESDAY, Jan. 20, 2015 (HealthDay News) -- A therapy that uses patients' own primitive blood cells may be able to reverse some of the effects of multiple sclerosis, a preliminary study suggests.
The findings, published Tuesday in the Journal of the American Medical Association, had experts cautiously optimistic.
But they also stressed that the study was small -- with around 150 patients -- and the benefits were limited to people who were in the earlier courses of multiple sclerosis (MS).
"This is certainly a positive development," said Bruce Bebo, the executive vice president of research for the National Multiple Sclerosis Society.
There are numerous so-called "disease-modifying" drugs available to treat MS -- a disease in which the immune system mistakenly attacks the protective sheath (called myelin) around fibers in the brain and spine, according to the society. Depending on where the damage is, symptoms include muscle weakness, numbness, vision problems and difficulty with balance and coordination.
But while those drugs can slow the progression of MS, they can't reverse disability, said Dr. Richard Burt, the lead researcher on the new study and chief of immunotherapy and autoimmune diseases at Northwestern University's Feinberg School of Medicine in Chicago.
His team tested a new approach: essentially, "rebooting" the immune system with patients' own blood-forming stem cells -- primitive cells that mature into immune-system fighters.
The researchers removed and stored stem cells from MS patients' blood, then used relatively low-dose chemotherapy drugs to -- as Burt described it -- "turn down" the patients' immune-system activity.
From there, the stem cells were infused back into patients' blood.
The rest is here:
Early Study Says Stem Cells May Reverse Multiple Sclerosis Disability
Chemicals that mimic estrogen hamper development of the stem cells responsible for making sperm in mice
The study is the first to suggest that low, brief exposures to bisphenol-A early in life can alter the stem cells responsible for producing sperm later in life. Credit: anyaivanova/Thinkstock
BPA and other estrogenic compounds hamper development of the stem cells responsible for producing sperm in mice, which suggests such exposure could contribute to declining sperm counts in men, according to a new study.
The study, published online today in PLoS Genetics, is the first to suggest that low, brief exposures to bisphenol-A, or other estrogens such as those used in birth control but found as water contaminants, early in life can alter the stem cells responsible for producing sperm later in life.
Exposure to estrogens is not simply affecting sperm being produced now, but impacting the stem cell population, and that will affect sperm produced throughout the lifetime, said Patricia Hunt, a geneticist at Washington State University who led the study.
BPA is a ubiquitous chemical found in most people and used to make polycarbonate plastic and found in some food cans and paper receipts. People also are exposed to synthetic estrogens used in birth control as they are commonly foundcontaminating water, even after treatment.
The U.S. Food and Drug Administration banned BPA from baby bottles in 2012 but maintains that BPA currently used in food containers and packaging is safe. And this week the European Food Safety Authority announced in a new assessment there is no consumer health risk from bisphenol-A exposure.
However, Hunts study adds to evidence that low doses of the compound may harm us.
Hunt and colleagues exposed some newborn mice to BPA and some newborn mice to a synthetic estrogen used in birth control pills and hormone therapy.
These exposurescomparable to human exposures to the compoundscaused permanent alterations to the stem cells responsible for sperm production, the authors wrote.
More here:
A Palm Beach County man who posed as a doctor specializing in stem cell therapy injections to treat sports injuries received a one-year jail sentence Thursday.
In a deal with the State Attorney's Office, Jon Rubenstein, 46, pleaded guilty to one count of unlicensed practice of health care profession, a charge punishable by up to five years in prison if there's a conviction.
It resolves a case that began last year with a complaint from the Florida Department of Health, which accused Rubenstein of offering a procedure platelet-rich plasma therapy to injured athletes, according to a Palm Beach County Sheriff's Office arrest report.
Palm Beach County Circuit Judge Glenn Kelley sentenced Rubenstein to two years probation, including one year in Palm Beach County Jail that may be eligible to be served on house arrest.
Rubenstein also must pay a $1,000 fine and complete 50 hours of community service, prosecutor Aaron Papero said.
The offense will not appear as a felony conviction on Rubenstein's record as long as he completes the terms of the agreement without any violations.
Outside the courtroom, Assistant Public Defender Trey Woodfin declined to comment about the case or the plea deal he negotiated with the prosecutor.
During a law enforcement investigation, Rubenstein told an undercover agent he was a doctor with the Center for Natural Healing and Regenerative Medicine.
State records identified him as a registered agent for a company with that name, and a second firm, Innovative Blood Technology, Inc., with a Margate, Fla., address.
Rubenstein advertised through a website under the name All Natural Sports Medicine, and touted his services on Twitter, Facebook and other social media, according to the arrest report.
View post:
Fake sports injury 'doctor' pleads guilty, gets jail sentence
"She #39;s Happy" RMG #39;s next Stem Cell Miracle
Meet Mary Taylor, she was blind for four years from wet and dry Macular Degeneration. Her son Richard, was a previous patient of Regenerative Medical Group, as he received treatment for his...
By: iManifestart
Read the original here:
Stem Cell Therapy | Recent Strides Quell Stem Cell Debate
Ethical concerns for stem cells for arthritis could be mute...maybe. Reports show that adult stem cells (Autologous) have been shown in recent studies to have significant effects on osteoarthritis...
By: Nathan Wei
See the original post here:
Stem Cell Therapy | Recent Strides Quell Stem Cell Debate - Video
Nutech Mediworld - Pioneering human embryonic stem cell therapy
An audio visual that features patients suffering from conditions considered incurable or terminal. And how they experienced significant improvement with human embryonic stem cell therapy at...
By: Resonance Consulting
Read more from the original source:
Nutech Mediworld - Pioneering human embryonic stem cell therapy - Video
Stem cell therapy may have helped patients with a form of multiple sclerosis, according to a preliminary study.
Patients with relapsing-remitting multiple sclerosis showed signs of improvement after being treated with their own, or autologous "nonmyeloablative hematopoietic stem cells," a class of blood-forming stem cells, the study found. It was published Tuesday in the Journal of the American Medical Association.
Half, or 41 patients, tested two years after treatment experienced significant improvement on the Expanded Disability Status Scale, a measure of disability. And of patients tested at 4 years, 23, or 64 percent, showed significant improvement. Four-year relapse-free survival was 80 percent and progression-free survival was 87 percent.
"To our knowledge, this is the first report of significant and sustained improvement in the EDSS score following any treatment for MS," stated the study. It was led by Dr. Richard K. Burt of Northwestern University in Chicago.
However, only limited conclusions can be drawn from the uncontrolled study, according to scientists who examined the results. While the therapy was associated with improvement, the stem cell transplant may not have been key. A conditioning regimen that partially depleted the stem cells before transplantation may have been responsible, said Dr. Stephen L. Hauser in a JAMA article accompanying the study.
"According to Carl Sagan, 'extraordinary claims require extraordinary evidence,' a standard that is not always met in this report, and not claimed by the authors. Even though the authors appropriately acknowledge many of the limitations associated with their case series, their statement that 'to our knowledge, this is the first report of significant and sustained improvement in the EDSS score following any treatment for MS' could be challenged," Hauser wrote.
Jeanne Loring, a stem cell researcher who studies multiple sclerosis and other neurodegenerative diseases, agreed that the results are far from conclusive.
"Multiple sclerosis is an autoimmune disease, meaning that the patients' own immune cells attack their own nervous systems," Loring said by email after examining the study. "The authors of the JAMA article treated MS patients with their own blood stem cells in the hope that these cells would replace some of the self-destructive immune cells."
However, the uneven course of MS makes it hard to draw conclusions, wrote Loring, who heads the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla.
"Most patients with MS have attacks, followed by recovery, followed by another attack. In a few of these patients, the blood stem cell treatment seemed to extend their time between attacks. It's important to understand that other treatments, including drugs, have shown similar modest improvements, so it's too soon to celebrate a stem cell therapy."
Go here to see the original:
Results from a preliminary study indicate that among patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation (low intensity stem cell transplantation) was associated with improvement in measures of disability and quality of life, according to a study in the January 20 issue of JAMA.
Fifty percent of patients with MS are unable to continue employment by 10 years from diagnosis or are unable to walk by 25 years. Despite an annual cost of approximately $47,000 per patient to treat MS, no therapy approved by the U.S. Food and Drug Administration has been shown to significantly reverse neurological disability or improve quality of life, according to background information in the article.
Multiple sclerosis is thought to be an immunemediated disorder of the central nervous system. Autologous (the use of one's own cells) hematopoietic (blood) stem cell transplantation (HSCT) is a form of immune suppression but unlike standard immune-based drugs, autologous HSCT is designed to reset rather than suppress the immune system. Richard K. Burt, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues studied the association of nonmyeloablative HSCT with neurological disability and other clinical outcomes in patients with relapsing-remitting MS (defined as acute relapses followed by partial or complete recovery and stable clinical manifestations between relapses; n = 123) or secondary-progressive MS (defined as a gradual progression of disability with or without superimposed relapses; n = 28) treated between 2003 and 2014.
Outcome analysis was available for 145 patients with an average follow-up of 2.5 years. On a measure of disability (Expanded Disability Status Scale [EDSS] score), there was significant improvement in 41 patients (50 percent of patients tested at 2 years) and in 23 patients (64 percent of patients tested at 4 years). "To our knowledge, this is the first report of significant and sustained improvement in the EDSS score following any treatment for MS," the authors write.
Receipt of HSCT was also associated with improvement in physical function, cognitive function and quality of life. There was also a reduction on another measure of clinical disease severity, volume of brain lesions associated with MS seen on magnetic resonance imaging (MRI). Four-year relapse-free survival was 80 percent and progression-free survival was 87 percent.
Patient selection is important in determining outcome, the researchers write. "In the post hoc analysis, the EDSS score did not improve in patients with secondary-progressive MS or in those with disease duration longer than 10 years."
The authors note the results are limited because this was an observational study without a control group. "Definitive conclusions will require a randomized trial; however, this analysis provides the rationale, appropriate patient selection, and therapeutic approach for a randomized study."
(doi:10.1001/jama.2014.17986; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: This study was made possible by financial support from the Danhakl family, the Cumming Foundation, the Zakat Foundation, the McNamara Purcell Foundation, and Morgan Stanley and Company. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Editorial: Hematopoietic Stem Cell Transplantation for MS
Read the original post:
Stem cell transplantation shows potential for reducing disability in patients with MS
An Airdrie man feels he has been duped out of thousands of dollars after receiving treatment for multiple sclerosis (MS).
Lee Chuckry, who has been dealing with MS for almost 20 years, says his symptoms have worsened since he received experimental, stem-cell therapy in India in 2013 from Regenetek Research INC, a Winnipeg-based company led by CEO Doug Broeska.
Its gotten much worse, said Chuckry of his condition, an autoimmune disorder that damages the insulating covers of nerve cells, leading to a wide range of symptoms and permanent neurological damage.
Chuckry explained he was diagnosed with MS about 20 years ago and is now dependant on a motorized scooter to get around.
The 47-year-old Airdrie man originally found Broeskas study online.
I was hoping for something that would put the breaks on the disease, said Chuckry.
Now, Chuckry is questioning Broeskas credentials as a medical researcher.
I did do my due diligence before going to India, and I thought everything was on the up and up, said Chuckry.
Chuckry explained since returning from India, where he spent $34,000 to receive the therapy, which consisted of widening the veins in his neck and injecting stem cells, he has experienced three MS attacks.
Excerpt from:
Published: January 19, 2015
Sharon Nordstrom feels ashamed for participating in a $38,000 multiple sclerosis stem cell treatment inIndia that was not all it was promoted to be. Submitted photo.
JONATHAN CHARLTON THE STARPHOENIX
Sharon Nordstrom feels ashamed for participating in a $38,000 multiple sclerosis stem cell treatment inIndia that was not all it was promoted to be.
Im going to be a real mouthpiece now for people who think theyre toosmartto fall for stuff like this, she said.
The WinnipegFreePress this week published aninvestigationinto Winnipeg-based Regenetek Research, finding that head researcher Doug Broeska fabricated his credentials, including his PhD, and overstated the effects of the stem-cell treatment.
The newspaper also discovered that the chairman of the medical ethics committee at the Inamdar Hospital in Pune,India, told Broeska his lack of credentials and followup violatedinternational ethical standards and ordered him to step down as principal investigator of the stem-cell study.
Broeska told theFreePress he was terminated only because it was decided to have a local principal investigator stationed inIndia.
TheFreePress further reported that the University of Winnipeg has cancelled a joint stem-cell treatment project involving Broeskas company.
Nordstrom says she last heard from Broeska on June 16, when he said in an email he would expel her from the trial after she questioned the absence of a followup care plan. For months, she kept her situation quiet.
Originally posted here:
Saskatoon woman snared in alleged fraudulent MS trial held in India
Shin splints/muscle atrophy three months after stem cell therapy by Harry Adelson, N.D.
Angela is a life-long triathlete. Ten years ago she developed severe shin splints in her left leg that resulted in atrophy of her lower leg muscles. Here, sh...
By: Harry Adelson, N.D.
Read more here:
Shin splints/muscle atrophy three months after stem cell therapy by Harry Adelson, N.D. - Video
Pet Stems Cell Therapy for Pets Prolong the life of your pet
http://petstems.com Pet Stems is cutting edge orally administered cell therapy designed for pets. No other company in the world offers this kind of nutritional cell therapy for pets. We love...
By: Pet Stems
Read more from the original source:
Pet Stems Cell Therapy for Pets Prolong the life of your pet - Video
Overview of Stem Cell Therapy at New Jersey Pain Management Clinics
http://nj-pain.com/treatments/stem-cell-procedure/ Stem Cell Therapy falls under regenerative medicine, and it is now a reality in musculoskeletal medicine. This includes stem cells being...
By: New Jersey Pain Network
Originally posted here:
Overview of Stem Cell Therapy at New Jersey Pain Management Clinics - Video
A Winnipeg-based company that has touted its ability to improve the lives of Multiple Sclerosis patients through stem cell therapy is now under the microscope after allegations of fraud from a client.
The CEO of Regenetek Research Inc. has been collecting thousands of dollars from Canadian patients looking for help. Some of the patients are now questioning the research and credentials of the man they know as Dr. Doug.
One of them is Lee Chuckry, 47. He has been living with MS for nearly two decades.
MS just keeps progressing, thats what it does. Hopefully I could stop it. That was my ultimate goal, Chuckry said in an interview with CTV News.
His efforts led him to Regenetek, and its CEO: Doug Broeska.
In testimonials, MS patients attributed miraculous medical improvement to experimental stem cell therapy. For $35,000, Regenetek patients were flown to India for the procedure.
Chuckry was one of the participants. But when he returned home, he says his symptoms worsened.
When he started digging deeper, he said, he found the doctor hed put his faith in wasnt what he claimed to be.
Im going to call Doug a con artist, Chuckry said. You are preying on people who are desperate. They are looking for hope of any sort.
Chuckry and at least one other patient have gone to the RCMP. They allege Broeska, who claims to hold a PhD and a Bachelor of Science, is a fraud who is operating as a medical researcher without proper credentials.
See original here:
Winnipeg company offering stem cell therapy is fraudulent, MS sufferer alleges
How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell
http://www.nextgenerationstemcell.com Stem Cell Therapy Stem Cell Research.
By: Jasen Kobobel
More:
How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell - Video
Dr Sherif Stem cell therapy on OA
lecture powerpoint.
By: Medical Center
The rest is here: